
Andrew Huntley
Managing Partner, Head of Healthcare
London, Ho Chi Minh City
Andrew Huntley is a Managing Partner of BDA. Having joined the co-founders in 1998, he established and oversaw BDA’s early Asian offices including Singapore, Shanghai and Hong Kong, subsequently co-managed BDA’s New York office from 2002 to 2005, and managed its London office from 2005 to 2018.
He now travels widely in Asia and Europe from his base in Ho Chi Minh City and oversees BDA’s global Healthcare & Life Sciences sector. Mr. Huntley has advised clients on transactions across Asia as well as in Europe and North America, including both blue chip corporate clients such as Arkema, Celestica, Clariant, Edenred, Henkel, Jardine Matheson, Johnson Matthey, Laird Group, Rexel, Sumitomo Chemical, SunGard, ThomsonReuters, Tata Motors and Weir Group as well as financial sponsors such as Actis, Ardian, Bregal Capital, EQT, LDC, Investcorp, Mekong Capital, Nova Capital, Prudential, Segulah, Seera and STIC. Before BDA, Mr. Huntley worked for the Jardine Matheson Group in HK, China, Taiwan and Vietnam. He acted as the Group Representative in Vietnam and had executive responsibility for Group businesses there and in Taiwan. Mr. Huntley was educated at Oxford University (MA Hons, Chinese). He is fluent in Mandarin and conversant in Vietnamese.
Recent transactions
Received investment from TA Associates
2023
Divested B Medical Systems to Azenta
2022
Agreed to divest East Syracuse, New York facility to LOTTE Corporation
2022
Debt and equity restructuring
2022
Acquired by Novo Holdings
2022
Investment from The Riverside Company
2021
Acquired by MicroPort
2021
Divested 100% to EagleTree Capital
2021
Divested 100% to by Escalent
2021
Acquired by Mindray
2021
Raised Series B round from ABC World Asia
2021
Divested Neoss to CareCapital
2020
Divested Escientia Life Sciences to Deccan Fine Chemicals
2020
Divested significant stake in Kehua Bio-Engineering to Gree Real Estate
2020
Divested majority stake to The Longreach Group
2019
Divested Model Solution to Hankook Tire
2018
Divested The Ritedose Corporation to AGIC and Humanwell
2017
Divested its 48.08% equity stake in Netas to ZTE
2017
Majority recapitalized by Galen Partners
2017
Divested CMC Biologics to Asahi Glass
2017